Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.

@article{Berman2013PhaseIS,
  title={Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.},
  author={Daniel S. Berman and Jamshid Maddahi and Balaji Tamarappoo and Johannes G Czernin and Raymond Taillefer and James E. Udelson and C Michael Gibson and Marybeth Devine and Joel Lazewatsky and Gajanan Bhat and Dana Washburn},
  journal={Journal of the American College of Cardiology},
  year={2013},
  volume={61 4},
  pages={469-77}
}

• Daniel S. Berman, Jamshid Maddahi, +8 authors Dana Washburn
• Published 2013 in Journal of the American College of Cardiology
• DOI:10.1016/j.jacc.2012.11.022

OBJECTIVES This was a phase II trial to assess flurpiridaz F 18 for safety and compare its diagnostic performance for positron emission tomography (PET) myocardial perfusion imaging (MPI) with Tc-99m single-photon emission computed tomography (SPECT) MPI with regard to image quality, interpretative certainty, defect magnitude, and detection of coronary artery disease (CAD) (≥50% stenosis) on invasive coronary angiography (ICA). BACKGROUND In pre-clinical and phase I studies, flurpiridaz F 18… CONTINUE READING

View on PubMed

Alternate Sources

Add to Library

Create Alert

Cite